TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05393856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-549
Description: PART A (open-label)~Period 1: single oral dose. Period 2: After PK evaluation of period 1. Period 3: After PK evaluation of period 2.~PART B (randomized)~* Period 1: a single oral dose of ZZ mg CG-549 on Day 1 in fed or fasted state.~* Period 2: a single oral dose of ZZ mg CG-549 on Day 1 in fasted or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-549
Description: PART A (open-label)~Period 1: single oral dose. Period 2: After PK evaluation of period 1. Period 3: After PK evaluation of period 2.~PART B (randomized)~* Period 1: a single oral dose of ZZ mg CG-549 on Day 1 in fed or fasted state.~* Period 2: a single oral dose of ZZ mg CG-549 on Day 1 in fasted or fed state.
Study: NCT04638283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Attainment Scaling
Description: Individual goals will be formulated and measured by Goal Attainment Scaling (GAS). GAS provides a method for quantifying the attainment of individualized goals, typically set in cognitive rehabilitation. Different levels of outcomes for each goal are operationalized in a five-point scale and given a numeric value. For each individual goal, minus two refers to the goal attainment much less than expected, minus one refers to a little less than expected, zero refers to expected outcome, plus one refers to a little bit better than expected and plus two refers to goal attainment much better than expected. The participants can establish as many goals as desired. Outcomes can be summed within different patient goals, as well as across patients to assess overall outcome of treatment outcomes.
Study: NCT02523911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone
Description: Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium sulfate/potassium sulfate/magnesium sulfate solution
Description: Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
Study: NCT03090529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The 12-week exercise-training program will include three sessions of aerobic exercise per week
Study: NCT01210833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandTutor System
Description: Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HandTutor System
Description: Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
Study: NCT01559454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 10-60 mg/day divided by 2-4 times a day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: 4-16 mg/day divided by 2-4 times a day for 6 months
Study: NCT03466606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre-habilitation
Description: Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
Study: NCT02523911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium sulfate/potassium sulfate/magnesium sulfate solution
Description: Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
Study: NCT01127451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: Denileukin diftitox intravenous infusion over 30-60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: Denileukin diftitox intravenous infusion over 30-60 minutes.
Study: NCT03181438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline Group
Description: t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
Study: NCT02750306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 10 mg tablet (may be increased to 20 mg tablet)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to suvorexant
Study: NCT03397628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11 for health
Study: NCT02003040

Intervention type: DEVICE
Intervention: Mespere Venus 1000 CVP System
Description: An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
Study: NCT00644631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
Study: NCT04602130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.
Study: NCT00672620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets
Study: NCT04602130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sponge Bathing
Description: The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sponge Bathing
Description: The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tub Bathing
Description: The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tub Bathing
Description: The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form.
Study: NCT01733732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® BALANCE Lubricant Eye Drops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SYSTANE® Gel
Study: NCT00672620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules
Study: NCT03247296

Intervention type: DRUG
Intervention: Sofosbuvir 400 mg, Daclatasvir, Ribavirin
Description: No intervention made this is an observational study to monitor the already existing protocols of the facility

Intervention type: DRUG
Intervention: Sofosbuvir 400 mg, Daclatasvir, Ribavirin
Description: No intervention made this is an observational study to monitor the already existing protocols of the facility
Study: NCT00892112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Immunoglobulins
Description: 2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: plasma volume expander
Description: 10 ml/kg BW will be administrated on four consecutive days.
Study: NCT00236301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLIMASTON (drug)
Description: CLIMASTON(drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 Beta-estradiol (2mg/day)and (1mg/day)
Description: 17 Beta-estradiol (2mg/day)and (1mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01435811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus challenge pool (GII.4, CIN-1)
Description: Norovirus challenge pool (GII.4, CIN-1)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Norovirus challenge pool (GII.4, CIN-1)
Description: Norovirus challenge pool (GII.4, CIN-1)
Study: NCT00814424

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monitored using currently marketed smart biteblock o2
Description: oral nasal CO2 monitoring and oxygen delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monitored using investigational smart biteblock
Description: monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
Study: NCT00919074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic duct stent
Description: Placement of a pancreatic duct stent to facilitate bile duct cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic wire placement
Description: Placement of a pancreatic wire to facilitate bile duct cannulation
Study: NCT03325244

Intervention type: OTHER
Intervention: EEG monitor
Description: sleep patterns will be monitored using EEG monitor

Intervention type: OTHER
Intervention: FitBit
Description: activity levels will be monitored
Study: NCT03656705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCCR-NK92 cells
Description: CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
Study: NCT00378352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epoetin alfa
Description: Randomized

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epoetin alfa
Description: Randomized
Study: NCT04419090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based centralized service and message
Description: Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based centralized service and message
Description: Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.
Study: NCT06449131

Intervention type: DRUG
Group type: OTHER
Intervention: Platelet-Rich Plasma and Fibrin Glue
Description: Allogenic platelet-rich plasma with fibrin glue (PRP-FG) was derived from blood obtained from a blood bank. Peripheral blood (400 ml) was collected from a donor with a matching ABO blood type, and rigorous viral safety tests were conducted. Concentrated PRP (10 ml) was obtained by subjecting the sample to centrifugation at 4000 g for 15 min to separate the plasma from the sedimented platelets.~Fibrinogen was extracted from the separated plasma using cryoprecipitation. After freezing at -70°C followed by thawing at 4°C, fibrinogen concentrate (20 ml) was prepared by centrifugation at 6500 × g for 5 min. The concentrated PRP was combined with fibrinogen (30 ml).~Thrombin was generated from the plasma isolated during the second centrifugation step. The ionic strength and pH were adjusted to precipitate prothrombin. The resulting precipitate was separated by centrifugation and dissolved in a calcium ion solution, resulting in a final volume of 5 ml of thrombin solution.
Study: NCT01094925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300mg
Description: Single oral dose of 300mg gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 600mg
Description: Single oral dose of 600mg gabapentin
Study: NCT03294330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC-Green KIT
Description: fluorescence lymphangiography with the use of IC-Green
Study: NCT04688424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling
Description: Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
Study: NCT00430248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.
Study: NCT03840603

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Film Array RP2 Assay guided
Description: Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.
Study: NCT01939704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Primary Care Intervention
Description: 30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Urgent Care Intervention
Description: 3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
Study: NCT01782443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept
Study: NCT00717639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic MR-Angiography
Description: Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
Study: NCT02629991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (IN-OXT)
Description: Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
Study: NCT01624948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid dose reduction
Description: Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
Study: NCT01129388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral